MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, ALNY made $3,713,937K in revenue. $328,168K in net income. Net profit margin of 8.84%.

Income Overview

Revenue
$3,713,937K
Net Income
$328,168K
Net Profit Margin
8.84%
EPS
$2.33
Unit: Thousand (K) dollars
Revenue Breakdown
    • US
    • Europe
    • Roche
    • Others

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-12-31
Total revenues
3,713,937
Cost of goods sold
677,166
Cost of collaborations and royalties
4,705
Research and development
1,319,775
Selling, general and administrative
1,210,713
Total operating costs and expenses
3,212,359
Income (loss) from operations
501,578
Interest expense
252,627
Interest income
111,470
Loss related to convertible debt
42,473
Other income (expense), net
5,204
Total other expense, net
-178,426
Income (loss) before income taxes
323,152
(provision for) benefit from income taxes
9,405
Net income (loss)
313,747
Unrealized gains (losses) on marketable securities
1,816
Foreign currency translation gains (losses)
11,624
Defined benefit pension plans, net of tax
-981
Net other comprehensive loss
14,421
Comprehensive income (loss)
328,168
Net income (loss) per common share, basic (in dollars per share)
2.39
Net income (loss) per common share, diluted (in dollars per share)
2.33
Weighted average common shares, basic (in shares)
131,004,000
Weighted average common shares, diluted (in shares)
134,684,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Non USOr Europe$34,921K Europe$88,049K US$68,467K Non USOr Europe$25,057K Europe$77,715K US$205,715K Non USOr Europe$31,234K Europe$79,429K US$62,126K Non USOr Europe$176,715K Europe$405,899K US$1,731,222K OXLUMO$191,437K GIVLAARI$308,487K ONPATTRO$172,789K Amvuttra$2,313,836K Other Collaborations$44,528K RegeneronPharmaceuticals Incorporation$113,957K Roche$394,881K Rare$499,924K TTR$2,486,625K Royalty$174,022K Collaborations$553,366K Product$2,986,549K Total revenues$3,713,937K Income (loss) fromoperations$501,578K Total operating costsand expenses$3,212,359K Defined benefit pensionplans, net of tax-$981K Foreign currencytranslation gains (losses)$11,624K Unrealized gains (losses)on marketable...$1,816K Income (loss) beforeincome taxes$323,152K Total other expense,net-$178,426K Other income(expense), net$5,204K Interest income$111,470K Selling, general andadministrative$1,210,713K Research and development$1,319,775K Cost ofcollaborations and royalties$4,705K Cost of goods sold$677,166K Net othercomprehensive loss$14,421K Net income (loss)$313,747K (provision for) benefitfrom income taxes$9,405K Loss related toconvertible debt$42,473K Interest expense$252,627K Comprehensive income (loss)$328,168K

ALNYLAM PHARMACEUTICALS, INC. (ALNY)

ALNYLAM PHARMACEUTICALS, INC. (ALNY)